JNBA Financial Advisors Lowers Holdings in Novo Nordisk A/S $NVO

JNBA Financial Advisors decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 15.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,676 shares of the company’s stock after selling 310 shares during the quarter. JNBA Financial Advisors’ holdings in Novo Nordisk A/S were worth $116,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth about $27,000. Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares during the period. Stone House Investment Management LLC acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $30,000. Disciplina Capital Management LLC raised its holdings in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the period. Finally, Spirit of America Management Corp NY acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $56.95 on Friday. The business has a 50 day simple moving average of $55.44 and a two-hundred day simple moving average of $63.22. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $120.56. The stock has a market capitalization of $254.27 billion, a P/E ratio of 15.64, a PEG ratio of 2.65 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NVO shares. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.